A Study of LY3361237 in Participants With Psoriasis
Status:
Recruiting
Trial end date:
2022-10-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about the safety and tolerability of
LY3361237 and any side effects that might be associated with it when given to participants
with psoriasis. LY3361237 will be administered by injections just under the skin. The study
will last up to 41 weeks and may include up to 15 visits to the study center.